西地那非联合贝前列素或阿托伐他汀治疗肺动脉高压的临床观察

目的比较西地那非联合阿托伐他汀、西地那非联合贝前列素治疗肺动脉高压的疗效及安全性。方法选择54例肺动脉高压患者随机分成2组,分别给予西地那非联合阿托伐他汀(A组)、西地那非联合贝前列素(B组)治疗,治疗前及治疗后6个月观察6 min步行距离(6MWD)、平均肺动脉压(mPAP)、肺血管阻力(PVR)和心脏指数(CI)。结果 2组均能增加6MWD,降低mPAP和PVR,提高CI,且西地那非联合贝前列素疗效更显著。2组间不良反应无明显差异,均未见严重不良反应。结论西地那非联合贝前列素治疗肺动脉高压的疗效优于西地那非联合阿托伐他汀,是一种安全有效的治疗方法。

Effect of Combination of Sildenafil and Beraprost or Atorvastin on Pulmonary Arterial Hypertension

OBJECTIVE To observe the clinical effect and safety of combination of sildenafil and atorvastin or beraprost on pulmonary arterial hypertension (PAH). METHODS Fifty-four patients with PAH were randomly divided into two groups and were given treatment with combination of sildenafil and atorvastin or combination of sildenafil and beraprost respectively. 6-Minute walk distance (6MWD), mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR) and cardiac index (CI) were observed after six months. RESULTS Two groups could both increase 6WMD, decrease mPAP and PVR and improve CI. The effect in the group given with combination of sildenafil and beraprost was more significant. There was no significant side-effect and severe adverse reaction in every group. CONCLUSION The effect of combination of sildenafil and beraprost is more significant than the combination of sildenafil and atorvastin on PAH. The combination of sildenafil and beraprost is safe and effective in treating PAH.